ARTICLE | Company News
Isis, Eli Lilly deal
September 27, 2004 7:00 AM UTC
Under an ongoing research deal, LLY licensed from ISIS rights to LY2275796, a second-generation antisense cancer compound that targets eukaryotic initiation factor-4E (eIF-4E). elF-4E is over-express...